FDA bestows accelerated approval on ImmunoGen's ovarian cancer drug, with confirmatory answer coming soon

Three and a half years ago, ImmunoGen ran up against an FDA brick wall. Its ovarian cancer drug, mirvetuximab soravtansine, failed a Phase III study, forcing the biotech to scale back and lay off more than two-thirds of its staff. Execs tightened their belts to preserve the cash they had left.